Acta Scientific Clinical Case Reports

Editorial Volume 1 Issue 7

Coronavirus Disease-2019 (COVID-19) Pandemic - What are we Missing

Pankaj Bansal*

Department of Rheumatology, Mayo Clinic Health System, Eau Claire, USA

*Corresponding Author: Pankaj Bansal, Department of Rheumatology, Mayo Clinic Health System, Eau Claire, USA.

Received: June 25, 2020; Published: August 01, 2020

×

 In December 2019, China faced the first known case of infection caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and as of June 23, 2020, 8,993,659 cases of the COVID-19 infection have been reported worldwide with 469,587 deaths globally [1]. The past 7 months have seen an unprecedented increase in publications related to a single disease, with 35,444 publications reported on the World Health Organization Global Research Database as of June 23, 2020 [2]. Despite this extraordinary effort by researchers and scientists across the world, no treatment has been proven to be effective so far. Although several trials on developing a vaccine are ongoing, until a safe and effective vaccine is available, the only effective strategy against this disease is mitigating the risk of contracting the infection by measures such as social distancing, hand washing and wearing masks [3].

×

References

  1. Coronavirus disease (COVID-2019) situation reports (2020).
  2. Yeo-The., et al. “An alarming retraction rate for scientific publications on Coronavirus Disease 2019 (COVID-19)”. Word Health Origination (2020).
  3. Coronavirus (2019).
  4. Gautret P., et al. “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”. The International Journal of Antimicrobial Agents (2020): 105949.
  5. Chen Z., et al. “Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial”. Epidemiology (2020).
  6. Yu B., et al. “Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19”. Emergency Medicine (2020).
  7. Chen J., et al. “[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]”. International Journal of Medical Sciences 49 (2020): 215-219.
  8. Geleris J., et al. “Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19”. The New England Journal of Medicine (2020).
  9. Magagnoli J., et al. “Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19”. Infectious Diseases (2020).
  10. Boulware DR., et al. “A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19”. The New England Journal of Medicine (2020).
  11. RECOVERY trial webpage.
  12. https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or
×

Citation

Citation: Pankaj Bansal. “Coronavirus Disease-2019 (COVID-19) Pandemic - What are we Missing" Acta Scientific Clinical Case Reports 1.8 (2020): 01-02.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 25, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US